MSTN and sarcopenia: The levels of myostatin may indicate sarcopenia in cirrhosis and since sarcopenia has been shown to be a risk factor for the development of ACLF, this study aimed to evaluate the role of myostatin levels and their association with the development of ACLF, and associated mortality, in patients with cirrhosis.